Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Inventory (2023 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Inventory for 3 consecutive years, with $5.5 million as the latest value for Q4 2025.

  • Quarterly Inventory rose 72.01% to $5.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.5 million through Dec 2025, up 72.01% year-over-year, with the annual reading at $5.5 million for FY2025, 72.01% up from the prior year.
  • Inventory for Q4 2025 was $5.5 million at Phathom Pharmaceuticals, up from $3.6 million in the prior quarter.
  • The five-year high for Inventory was $5.5 million in Q4 2025, with the low at $111000.0 in Q2 2023.
  • Average Inventory over 3 years is $2.5 million, with a median of $3.1 million recorded in 2024.
  • The sharpest move saw Inventory surged 2702.7% in 2024, then rose 16.07% in 2025.
  • Over 3 years, Inventory stood at $1.2 million in 2023, then soared by 165.56% to $3.2 million in 2024, then surged by 72.01% to $5.5 million in 2025.
  • According to Business Quant data, Inventory over the past three periods came in at $5.5 million, $3.6 million, and $3.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.